Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

Using Quantitative Computed Tomographic Imaging to Understand Chronic Obstructive Pulmonary Disease and Fibrotic Interstitial Lung Disease: State of the Art and Future Directions.

Castillo-Saldana D, Hague CJ, Coxson HO, Ryerson CJ.

J Thorac Imaging. 2019 Aug 7. doi: 10.1097/RTI.0000000000000440. [Epub ahead of print]

PMID:
31397750
2.

Mobile Health Monitoring in Patients with Idiopathic Pulmonary Fibrosis.

Marcoux V, Wang M, Burgoyne SJ, Fell CD, Ryerson CJ, Sajobi TT, Johannson KA.

Ann Am Thorac Soc. 2019 Jun 26. doi: 10.1513/AnnalsATS.201904-335RL. [Epub ahead of print] No abstract available.

PMID:
31242394
3.

Diagnostic Likelihood Thresholds that Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis.

Walsh SLF, Lederer DJ, Ryerson CJ, Kolb M, Maher TM, Nusser R, Poletti V, Richeldi L, Vancheri C, Wilsher ML, Antoniou KM, Behr J, Bendstrup E, Brown KK, Corte TJ, Cottin V, Crestani B, Flaherty KR, Glaspole IN, Grutters J, Inoue Y, Kondoh Y, Kreuter M, Johannson KA, Ley B, Martinez FJ, Molina-Molina M, Morais A, Nunes H, Raghu G, Selman M, Spagnolo P, Taniguchi H, Tomassetti S, Valeyre D, Wijsenbeek M, Wuyts WA, Wells AU.

Am J Respir Crit Care Med. 2019 Jun 26. doi: 10.1164/rccm.201903-0493OC. [Epub ahead of print]

4.

Nocturnal hypoxaemia in interstitial lung disease: An easy target to treat?

Ryerson CJ, Vahidy S.

Respirology. 2019 Jun 10. doi: 10.1111/resp.13605. [Epub ahead of print] No abstract available.

5.

Impact of Psychological Deficits and Pain on Physical Activity of Patients with Interstitial Lung Disease.

Hur SA, Guler SA, Khalil N, Camp PG, Guenette JA, Ryerson CJ.

Lung. 2019 Aug;197(4):415-425. doi: 10.1007/s00408-019-00242-3. Epub 2019 Jun 1.

PMID:
31154459
6.

Supplemental oxygen for the management of dyspnea in interstitial lung disease.

Schaeffer MR, Molgat-Seon Y, Ryerson CJ, Guenette JA.

Curr Opin Support Palliat Care. 2019 Sep;13(3):174-178. doi: 10.1097/SPC.0000000000000434.

PMID:
31145136
7.

Exercise Pathophysiology in Interstitial Lung Disease.

Molgat-Seon Y, Schaeffer MR, Ryerson CJ, Guenette JA.

Clin Chest Med. 2019 Jun;40(2):405-420. doi: 10.1016/j.ccm.2019.02.011. Review.

PMID:
31078218
8.

Costs of Workplace Productivity Loss in Patients With Fibrotic Interstitial Lung Disease.

Algamdi M, Sadatsafavi M, Fisher JH, Morisset J, Johannson KA, Fell CD, Kolb M, Manganas H, Cox G, Gershon AS, Halayko AJ, Hambly N, Khalil N, Shapera S, To T, Wilcox PG, Guler S, Ryerson CJ.

Chest. 2019 Apr 30. pii: S0012-3692(19)30885-2. doi: 10.1016/j.chest.2019.04.016. [Epub ahead of print]

9.

Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage.

Ryerson CJ, Kolb M, Richeldi L, Lee J, Wachtlin D, Stowasser S, Poletti V.

ERJ Open Res. 2019 Apr 29;5(2). pii: 00127-2018. doi: 10.1183/23120541.00127-2018. eCollection 2019 Apr.

10.

Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis.

Moore C, Blumhagen RZ, Yang IV, Walts A, Powers J, Walker T, Bishop M, Russell P, Vestal B, Cardwell J, Markin CR, Mathai SK, Schwarz MI, Steele MP, Lee J, Brown KK, Loyd JE, Crapo JD, Silverman EK, Cho MH, James JA, Guthridge JM, Cogan JD, Kropski JA, Swigris JJ, Bair C, Kim DS, Ji W, Kim H, Song JW, Maier LA, Pacheco KA, Hirani N, Poon AS, Li F, Jenkins RG, Braybrooke R, Saini G, Maher TM, Molyneaux PL, Saunders P, Zhang Y, Gibson KF, Kass DJ, Rojas M, Sembrat J, Wolters PJ, Collard HR, Sundy JS, O'Riordan T, Strek ME, Noth I, Ma SF, Porteous MK, Kreider ME, Patel NB, Inoue Y, Hirose M, Arai T, Akagawa S, Eickelberg O, Fernandez IE, Behr J, Mogulkoc N, Corte TJ, Glaspole I, Tomassetti S, Ravaglia C, Poletti V, Crestani B, Borie R, Kannengiesser C, Parfrey H, Fiddler C, Rassl D, Molina-Molina M, Machahua C, Worboys AM, Gudmundsson G, Isaksson HJ, Lederer DJ, Podolanczuk AJ, Montesi SB, Bendstrup E, Danchel V, Selman M, Pardo A, Henry MT, Keane MP, Doran P, Vašáková M, Sterclova M, Ryerson CJ, Wilcox PG, Okamoto T, Furusawa H, Miyazaki Y, Laurent G, Baltic S, Prele C, Moodley Y, Shea BS, Ohta K, Suzukawa M, Narumoto O, Nathan SD, Venuto DC, Woldehanna ML, Kokturk N, de Andrade JA, Luckhardt T, Kulkarni T, Bonella F, Donnelly SC, McElroy A, Armstong ME, Aranda A, Carbone RG, Puppo F, Beckman KB, Nickerson DA, Fingerlin TE, Schwartz DA.

Am J Respir Crit Care Med. 2019 Jul 15;200(2):199-208. doi: 10.1164/rccm.201810-1891OC.

11.

Patient Registries in Idiopathic Pulmonary Fibrosis.

Culver DA, Behr J, Belperio JA, Corte TJ, de Andrade JA, Flaherty KR, Gulati M, Huie TJ, Lancaster LH, Roman J, Ryerson CJ, Kim HJ.

Am J Respir Crit Care Med. 2019 Jul 15;200(2):160-167. doi: 10.1164/rccm.201902-0431CI.

12.

Qualitative dimensions of exertional dyspnea in fibrotic interstitial lung disease.

Schaeffer MR, Guenette JA, Ramsook AH, Molgat-Seon Y, Mitchell RA, Wilkie SS, Dhillon SS, Sheel AW, Ryerson CJ.

Respir Physiol Neurobiol. 2019 Aug;266:1-8. doi: 10.1016/j.resp.2019.04.004. Epub 2019 Apr 12.

PMID:
30986534
13.

A smartphone oximeter with a fingertip probe for use during exercise training: usability, validity and reliability in individuals with chronic lung disease and healthy controls.

Chan C, Inskip JA, Kirkham AR, Ansermino JM, Dumont G, Li LC, Ho K, Novak Lauscher H, Ryerson CJ, Hoens AM, Chen T, Garde A, Road JD, Camp PG.

Physiotherapy. 2019 Sep;105(3):297-306. doi: 10.1016/j.physio.2018.07.015. Epub 2018 Oct 26.

PMID:
30876715
14.

Body composition, muscle function, and physical performance in fibrotic interstitial lung disease: a prospective cohort study.

Guler SA, Hur SA, Lear SA, Camp PG, Ryerson CJ.

Respir Res. 2019 Mar 12;20(1):56. doi: 10.1186/s12931-019-1019-9.

15.

Pulmonary physiology is poorly associated with radiological extent of disease in systemic sclerosis-associated interstitial lung disease.

Jhajj A, Gill HP, Hague CJ, Murphy D, Elicker B, Soon J, Sulaiman N, Castillo-Saldana D, Wilcox PG, Dunne J, Lee JS, Wolters PJ, Ley B, Jones KD, Morisset J, Ryerson CJ.

Eur Respir J. 2019 May 2;53(5). pii: 1802182. doi: 10.1183/13993003.02182-2018. Print 2019 May. No abstract available.

PMID:
30846470
16.

YouTube Videos as a Source of Misinformation on Idiopathic Pulmonary Fibrosis.

Goobie GC, Guler SA, Johannson KA, Fisher JH, Ryerson CJ.

Ann Am Thorac Soc. 2019 May;16(5):572-579. doi: 10.1513/AnnalsATS.201809-644OC.

PMID:
30608877
17.

Role of a Regional Multidisciplinary Conference in the Diagnosis of Interstitial Lung Disease.

Grewal JS, Morisset J, Fisher JH, Churg AM, Bilawich AM, Ellis J, English JC, Hague CJ, Khalil N, Leipsic J, Mayo J, Muller NL, Murphy D, Wright JL, Ryerson CJ.

Ann Am Thorac Soc. 2019 Apr;16(4):455-462. doi: 10.1513/AnnalsATS.201811-794OC.

PMID:
30608873
18.

Systematic review of content and quality of idiopathic pulmonary fibrosis review articles.

Milne KM, Chan C, Fisher JH, de Boer K, Ryerson CJ.

ERJ Open Res. 2018 Dec 21;4(4). pii: 00156-2018. doi: 10.1183/23120541.00156-2018. eCollection 2018 Oct.

19.

Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis.

Khalil N, Manganas H, Ryerson CJ, Shapera S, Cantin AM, Hernandez P, Turcotte EE, Parker JM, Moran JE, Albert GR, Sawtell R, Hagerimana A, Laurin P, Gagnon L, Cesari F, Kolb M.

Eur Respir J. 2019 Mar 18;53(3). pii: 1800663. doi: 10.1183/13993003.00663-2018. Print 2019 Mar.

20.

Lumpers versus splitters: What to do with suspected idiopathic pulmonary fibrosis?

Ryerson CJ.

Respirology. 2019 Apr;24(4):300-301. doi: 10.1111/resp.13442. Epub 2018 Nov 15. No abstract available.

21.

Successful lung transplantation in an HIV seropositive patient with desquamative interstitial pneumonia: a case report.

Ong S, Levy RD, Yee J, Partovi N, Churg A, Roméo P, Chalaoui J, Nador R, Wright A, Manganas H, Ryerson CJ.

BMC Pulm Med. 2018 Oct 16;18(1):162. doi: 10.1186/s12890-018-0727-0.

22.

Minimal Important Difference for Physical Activity and Validity of the International Physical Activity Questionnaire in Interstitial Lung Disease.

Hur SA, Guler SA, Khalil N, Camp PG, Guenette JA, Swigris JJ, Ryerson CJ.

Ann Am Thorac Soc. 2019 Jan;16(1):107-115. doi: 10.1513/AnnalsATS.201804-265OC.

PMID:
30211616
23.

Does Systemic Sclerosis-associated Interstitial Lung Disease Burn Out? Specific Phenotypes of Disease Progression.

Guler SA, Winstone TA, Murphy D, Hague C, Soon J, Sulaiman N, Li KH, Dunne J, Wilcox PG, Ryerson CJ.

Ann Am Thorac Soc. 2018 Dec;15(12):1427-1433. doi: 10.1513/AnnalsATS.201806-362OC.

PMID:
30188737
24.

Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.

Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F, Flaherty KR, Wells A, Martinez FJ, Azuma A, Bice TJ, Bouros D, Brown KK, Collard HR, Duggal A, Galvin L, Inoue Y, Jenkins RG, Johkoh T, Kazerooni EA, Kitaichi M, Knight SL, Mansour G, Nicholson AG, Pipavath SNJ, Buendía-Roldán I, Selman M, Travis WD, Walsh S, Wilson KC; American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society.

Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68. doi: 10.1164/rccm.201807-1255ST.

PMID:
30168753
25.

Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary Fibrosis.

Spagnolo P, Kreuter M, Maher TM, Wuyts W, Bonella F, Corte TJ, Kopf S, Weycker D, Kirchgaessler KU, Ryerson CJ.

Respiration. 2018;96(4):314-322. doi: 10.1159/000489668. Epub 2018 Jul 19.

26.

Unclassifiable interstitial lung disease: from phenotyping to possible treatments.

Guler SA, Ryerson CJ.

Curr Opin Pulm Med. 2018 Sep;24(5):461-468. doi: 10.1097/MCP.0000000000000509. Review.

PMID:
30004990
27.

Heterogeneity in Unclassifiable Interstitial Lung Disease. A Systematic Review and Meta-Analysis.

Guler SA, Ellison K, Algamdi M, Collard HR, Ryerson CJ.

Ann Am Thorac Soc. 2018 Jul;15(7):854-863. doi: 10.1513/AnnalsATS.201801-067OC.

PMID:
29779392
28.

Oesophageal diameter is associated with severity but not progression of systemic sclerosis-associated interstitial lung disease.

Winstone TA, Hague CJ, Soon J, Sulaiman N, Murphy D, Leipsic J, Dunne JV, Wilcox PG, Ryerson CJ.

Respirology. 2018 Oct;23(10):921-926. doi: 10.1111/resp.13309. Epub 2018 Apr 11.

PMID:
29641847
29.

Diagnostic criteria for idiopathic pulmonary fibrosis - Authors' reply.

Lynch DA, Sverzellati N, Travis WD, Colby TV, Inoue Y, Nicholson AG, Raoof S, Richeldi L, Ryerson CJ, Ryu JH.

Lancet Respir Med. 2018 Feb;6(2):e7. doi: 10.1016/S2213-2600(18)30021-3. No abstract available.

PMID:
29413090
30.

The increasing mortality of idiopathic pulmonary fibrosis: fact or fallacy?

Ryerson CJ, Kolb M.

Eur Respir J. 2018 Jan 18;51(1). pii: 1702420. doi: 10.1183/13993003.02420-2017. Print 2018 Jan. No abstract available.

31.

Neurophysiological mechanisms of exertional dyspnoea in fibrotic interstitial lung disease.

Schaeffer MR, Ryerson CJ, Ramsook AH, Molgat-Seon Y, Wilkie SS, Dhillon SS, Mitchell RA, Sheel AW, Khalil N, Camp PG, Guenette JA.

Eur Respir J. 2018 Jan 18;51(1). pii: 1701726. doi: 10.1183/13993003.01726-2017. Print 2018 Jan.

32.

Reply to Moodley: A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease.

Ryerson CJ, Walsh SLF, Collard HR; all authors.

Am J Respir Crit Care Med. 2018 May 15;197(10):1366-1367. doi: 10.1164/rccm.201712-2515LE. No abstract available.

PMID:
29342368
33.

Exertional hypoxemia is more severe in fibrotic interstitial lung disease than in COPD.

Du Plessis JP, Fernandes S, Jamal R, Camp P, Johannson K, Schaeffer M, Wilcox PG, Guenette JA, Ryerson CJ.

Respirology. 2018 Apr;23(4):392-398. doi: 10.1111/resp.13226. Epub 2017 Nov 28.

PMID:
29193512
34.

Oxygen Prescription in Interstitial Lung Disease: 2.5 Billion Years in the Making.

Morisset J, Ryerson CJ, Johannson KA.

Ann Am Thorac Soc. 2017 Dec;14(12):1755-1756. doi: 10.1513/AnnalsATS.201708-675ED. No abstract available.

PMID:
29192812
35.

The Fine Line between Success and Failure in Scleroderma Lung Fibrosis Trials.

Ryerson CJ, Denton CP.

Am J Respir Crit Care Med. 2018 Mar 1;197(5):553-554. doi: 10.1164/rccm.201711-2268ED. No abstract available.

PMID:
29186664
36.

Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper.

Lynch DA, Sverzellati N, Travis WD, Brown KK, Colby TV, Galvin JR, Goldin JG, Hansell DM, Inoue Y, Johkoh T, Nicholson AG, Knight SL, Raoof S, Richeldi L, Ryerson CJ, Ryu JH, Wells AU.

Lancet Respir Med. 2018 Feb;6(2):138-153. doi: 10.1016/S2213-2600(17)30433-2. Epub 2017 Nov 15. Review.

37.

The Many Faces of Hypersensitivity Pneumonitis.

Churg A, Ryerson CJ.

Chest. 2017 Sep;152(3):458-460. doi: 10.1016/j.chest.2017.03.024. No abstract available.

PMID:
28889874
38.

Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.

Vancheri C, Kreuter M, Richeldi L, Ryerson CJ, Valeyre D, Grutters JC, Wiebe S, Stansen W, Quaresma M, Stowasser S, Wuyts WA; INJOURNEY Trial Investigators.

Am J Respir Crit Care Med. 2018 Feb 1;197(3):356-363. doi: 10.1164/rccm.201706-1301OC.

PMID:
28889759
39.

Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study.

Walsh SLF, Maher TM, Kolb M, Poletti V, Nusser R, Richeldi L, Vancheri C, Wilsher ML, Antoniou KM, Behr J, Bendstrup E, Brown K, Calandriello L, Corte TJ, Cottin V, Crestani B, Flaherty K, Glaspole I, Grutters J, Inoue Y, Kokosi M, Kondoh Y, Kouranos V, Kreuter M, Johannson K, Judge E, Ley B, Margaritopoulos G, Martinez FJ, Molina-Molina M, Morais A, Nunes H, Raghu G, Ryerson CJ, Selman M, Spagnolo P, Taniguchi H, Tomassetti S, Valeyre D, Wijsenbeek M, Wuyts W, Hansell D, Wells A; IPF Project Consortium.

Eur Respir J. 2017 Aug 31;50(2). pii: 1700936. doi: 10.1183/13993003.00936-2017. Print 2017 Aug.

40.

Determinants and outcomes of prolonged anxiety and depression in idiopathic pulmonary fibrosis.

Glaspole IN, Watson AL, Allan H, Chapman S, Cooper WA, Corte TJ, Ellis S, Grainge C, Goh N, Hopkins P, Keir G, Macansh S, Mahar A, Moodley Y, Reynolds PN, Ryerson CJ, Walters EH, Zappala CJ, Holland AE.

Eur Respir J. 2017 Aug 17;50(2). pii: 1700168. doi: 10.1183/13993003.00168-2017. Print 2017 Aug. No abstract available.

41.

Supplemental oxygen and dypsnoea in interstitial lung disease: absence of evidence is not evidence of absence.

Schaeffer MR, Molgat-Seon Y, Ryerson CJ, Guenette JA.

Eur Respir Rev. 2017 Aug 9;26(145). pii: 170033. doi: 10.1183/16000617.0033-2017. Print 2017 Sep 30. No abstract available.

42.

Severity and features of frailty in systemic sclerosis-associated interstitial lung disease.

Guler SA, Kwan JM, Winstone TA, Milne KM, Dunne JV, Wilcox PG, Ryerson CJ.

Respir Med. 2017 Aug;129:1-7. doi: 10.1016/j.rmed.2017.05.012. Epub 2017 May 25.

43.

Supplemental Oxygen in Interstitial Lung Disease: An Art in Need of Science.

Johannson KA, Pendharkar SR, Mathison K, Fell CD, Guenette JA, Kalluri M, Kolb M, Ryerson CJ.

Ann Am Thorac Soc. 2017 Sep;14(9):1373-1377. doi: 10.1513/AnnalsATS.201702-137OI.

PMID:
28644693
44.

Pathologic Separation of Chronic Hypersensitivity Pneumonitis From Fibrotic Connective Tissue Disease-associated Interstitial Lung Disease.

Churg A, Wright JL, Ryerson CJ.

Am J Surg Pathol. 2017 Oct;41(10):1403-1409. doi: 10.1097/PAS.0000000000000885.

PMID:
28614213
45.

Patient and health care professional perspectives on using telehealth to deliver pulmonary rehabilitation.

Inskip JA, Lauscher HN, Li LC, Dumont GA, Garde A, Ho K, Hoens AM, Road JD, Ryerson CJ, Camp PG.

Chron Respir Dis. 2018 Feb;15(1):71-80. doi: 10.1177/1479972317709643. Epub 2017 Jun 1.

46.

Effects of hyperoxia on dyspnoea and exercise endurance in fibrotic interstitial lung disease.

Schaeffer MR, Ryerson CJ, Ramsook AH, Molgat-Seon Y, Wilkie SS, Dhillon SS, Mitchell RA, Sheel AW, Khalil N, Camp PG, Guenette JA.

Eur Respir J. 2017 May 25;49(5). pii: 1602494. doi: 10.1183/13993003.02494-2016. Print 2017 May. No abstract available.

47.

Cough is less common and less severe in systemic sclerosis-associated interstitial lung disease compared to other fibrotic interstitial lung diseases.

Cheng JZ, Wilcox PG, Glaspole I, Corte TJ, Murphy D, Hague CJ, Ryerson CJ.

Respirology. 2017 Nov;22(8):1592-1597. doi: 10.1111/resp.13084. Epub 2017 May 23.

PMID:
28544079
48.

In Response.

Flexman AM, Roughead T, Fisher JH, Sewell D, Ryerson CJ.

Anesth Analg. 2017 May;124(5):1742-1743. doi: 10.1213/ANE.0000000000002035. No abstract available.

PMID:
28426590
49.

A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease. An International Working Group Perspective.

Ryerson CJ, Corte TJ, Lee JS, Richeldi L, Walsh SLF, Myers JL, Behr J, Cottin V, Danoff SK, Flaherty KR, Lederer DJ, Lynch DA, Martinez FJ, Raghu G, Travis WD, Udwadia Z, Wells AU, Collard HR.

Am J Respir Crit Care Med. 2017 Nov 15;196(10):1249-1254. doi: 10.1164/rccm.201702-0400PP. No abstract available.

50.

Reply: Acute Exacerbation of Idiopathic Pulmonary Fibrosis.

Corte TJ, Ryerson CJ, Collard HR.

Am J Respir Crit Care Med. 2017 Feb 15;195(4):542-543. doi: 10.1164/rccm.201610-2025LE. No abstract available.

PMID:
28199161

Supplemental Content

Loading ...
Support Center